Greece’s four top banks are expected to need an extra capital injection of about 5 billion euros (US$6.9 billion), local media said on Sunday, as the country’s international lenders prepared for a new audit of Greek finances.
The Bank of Greece is currently evaluating the restructuring plans of the country’s four main lenders — National Bank, Alpha Bank, Piraeus Bank and Eurobank — before releasing stress test results that will show whether they can absorb possible future shocks from bad loans.
The Ethnos newspaper reported that the central bank’s preliminary estimates put the banks’ capital needs at about 5 billion euros, while Realnews said it would be about 4.5 euros to 4.8 billion euros.
The central bank said official results would be published by early next month.
Officials from the EU, the European Central Bank (ECB) and IMF were yesterday to begin their latest audit of Greek finances to decide whether a new tranche of aid will be released.
The so-called troika of lenders — the EU, IMF and the ECB —will also meet with Greek Finance Minister Yannis Stournaras.
Last month, Bank of Greece Governor George Provopoulos warned of rising bad loans, saying the “late repayment of loans could lead to a reduction of banks’ capital and the need for [new] capital to pay high commissions.”
The Greek banking sector underwent radical restructuring and consolidation last year under the terms of the country’s bailout deal with the EU, IMF and the ECB.
The four top banks were recapitalized as part of the terms included in the latest EU-IMF bailout deal.
A period of consolidation of the banking sector followed, with the big four rapidly acquiring smaller rivals and the subsidiaries of foreign banks who had pulled out.
A sum of 50 billion euros from the rescue loans was earmarked for the recapitalization of banks following the heavy losses they suffered by taking part in a write-down of privately-held Greek government bonds in 2012.
Meanwhile, Greece’s main opposition leader is certain a left-wing government will be in power by early next year and its top priority will be to negotiate a lightening of the country’s “unsustainable debt,” according to an interview published in a Sunday newspaper.
The present coalition government of conservatives and socialists could collapse this year if the Radical Left Coalition wins the May European election by a big margin, party leader Alexis Tsipras told To Vima.
Tsipras, the European Left’s candidate for the presidency of the European Commission, pledges to keep Greece in the eurozone and says he does not seek special treatment for Greece.
However, he added that if Greece’s eurozone partners do not agree on further cutting the country’s debt, he would stop servicing it.
The debt cutting negotiations will be the subject of an emergency EU summit that Tsipras will demand if his party forms a government.
Asked what would be his trump card in the negotiations, Tsipras said: “Europe knows Greece is the powerful energy partner of the year 2020,” referring to prospects for significant gas and oil finds in the Eastern Mediterranean, still at a stage of early exploration.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March